22157.jpg
Global Infectious Disease Treatment Market to 2029 - Featuring Pfizer, Abbvie and Alere Among Others
01 avr. 2022 06h38 HE | Research and Markets
Dublin, April 01, 2022 (GLOBE NEWSWIRE) -- The "Infectious Disease Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
22157.jpg
Global Infectious Disease Treatments Market Report 2021, Featuring Abbott, AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Novartis and Roche
24 déc. 2021 06h23 HE | Research and Markets
Dublin, Dec. 24, 2021 (GLOBE NEWSWIRE) -- The "Global Markets for Infectious Disease Treatments" report has been added to ResearchAndMarkets.com's offering. The global market for infectious...
new logo.jpg
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
09 nov. 2020 16h10 HE | Immutep Limited
Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release...
new logo.jpg
Immutep Announces Australian Patent Grant For IMP701 Antibody
09 nov. 2020 08h00 HE | Immutep Limited
Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 2015229103 entitled “Antibody molecules...
OnCore Biopharma, Inc.
OnCore Biopharma Agrees to Acquire Enantigen Therapeutics
01 oct. 2014 02h00 HE | OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Oct. 1, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biotechnology company focused on the research, development and commercialization of oral...